



Bionano Genomics Announces Speaker Lineup for 2022 China Symposium

March 25, 2022

SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: [BNGO](#)), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the final speaker lineup for its 2022 China Symposium. The Symposium will be held March 26, 2022, and features 9 presentations from leading researchers in China as well as opening messages from Erik Holmlin, PhD, Bionano's president and chief executive officer, and Alka Chaubey, PhD, FACMG, Bionano's chief medical officer.

Presentations at the China Symposium will highlight the latest research on OGM in a variety of applications spanning key clinical areas: constitutional disease, hematological disorders, and solid tumors. Researchers will share findings related to human fertility, prenatal genetics, ovarian cancer, and acute myelogenous leukemia, among other topics. The China Symposium follows the four-day Symposium 2022 hosted for North America and Europe, the Middle East and Africa in January. Dr. Chaubey's presentation from Bionano will share highlights of that event for attendees in China. All the presentations except for those from Bionano leadership will be hosted in Mandarin.

"We believe our commitment to access across global regions is critical to delivering on our mission to elevate the health and wellness of all people by transforming the way the world sees the genome. Bionano looks forward to featuring researchers from across China for this regional Symposium event," said Dr. Holmlin. "The OGM community in China continues to grow, and this event will be an opportunity for attendees to share data and exchange ideas in pursuit of genomic discovery. I am looking forward to seeing our customers showcase their accomplishments with OGM at the 2022 China Symposium."

China Symposium Speakers:

Speaker	Organization	Topic
Erik Holmlin	Bionano Genomics, President and CEO	Welcome: Transforming the way the world sees the genome
Alka Chaubey	Bionano Genomics, CMO	2022 Global Symposium Highlights
Jiang Yulin	Peking Union Medical College Hospital	Clinical application of OGM in the detection of complicated prenatal genetic diseases: Reflections and case sharing
Gao Yuan	Hospital for Reproductive Medicine Affiliated with Shandong University	What can OGM do when balanced translocations are not just balanced translocations?
Dong Zirui	Chinese University of Hong Kong (CUHK)	Detection and study of chromosomal structural variation in infertility
Zhang Shuo	Obstetrics and Gynecology Hospital Fudan University (Red House Hospital)	The value of OGM in the diagnosis of occult mutual translocation carriers
Wang Hao	Hangzhou Obstetrics and Gynecology Hospital	Cytogenomic adoption with OGM to detect complicated insertion and inversion of chromosomes
Lai Yi	West China Second University Hospital	A clinical case study of a complex rearrangement of chromosome 9
Yu Jinpu	Tianjin Medical University Cancer Institute and Hospital	Practice and exploration of OGM technique in an analysis of large segment structural abnormality of ovarian cancer
Li Zhigang	Beijing Children's Hospital Capital Medical University	OGM can discover more complicated structural variation in children with AML
Ye Feng	Genome Precision	Study on genome structure variation of immortalized B lymphocyte strain

Registration for 2022 China Symposium is available online at: <https://dxy.me/pCuWKZ>

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company's mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit

bionanogenomics.com, lineagen.com or biodiscovery.com.

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the expected dates, presentations, findings and areas of discussion at 2022 China Symposium. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business, the 2022 China Symposium and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements in existing technologies; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2021 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTS

Company Contact:

Erik Holmlin, CEO

Bionano Genomics, Inc.

+1 (858) 888-7610

eholmlin@bionanogenomics.com

Investor Relations:

Amy Conrad

Juniper Point

+1 (858) 366-3243

amy@juniper-point.com



Source: Bionano Genomics